AnaptysBio (ANAB) Competitors

AnaptysBio (NASDAQ:ANAB) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Is ANAB or VCEL more profitable?

Vericel has a net margin of 1.56% compared to AnaptysBio's net margin of -289.75%. Vericel's return on equity of 1.48% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-289.75%	-287.94%	-37.25%
Vericel	1.56%	1.48%	0.96%

Which has higher valuation and earnings, ANAB or VCEL?

Vericel has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$91.28M	6.78	-$163.62M	-$5.21	-3.87
Vericel	$237.22M	8.62	-$3.18M	$0.18	226.67

Which has more volatility and risk, ANAB or VCEL?

AnaptysBio has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.

Does the media favor ANAB or VCEL?

In the previous week, Vericel had 5 more articles in the media than AnaptysBio. MarketBeat recorded 9 mentions for Vericel and 4 mentions for AnaptysBio. Vericel's average media sentiment score of 1.44 beat AnaptysBio's score of 1.07 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ANAB or VCEL?

AnaptysBio presently has a consensus price target of $33.63, indicating a potential upside of 66.63%. Vericel has a consensus price target of $60.86, indicating a potential upside of 49.16%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.70
Vericel	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer ANAB or VCEL?

AnaptysBio received 20 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 66.25% of users gave AnaptysBio an outperform vote while only 61.85% of users gave Vericel an outperform vote.

Company	Underperform	Outperform
AnaptysBio	Outperform Votes 375 66.25%	Underperform Votes 191 33.75%
Vericel	Outperform Votes 355 61.85%	Underperform Votes 219 38.15%

Summary

Vericel beats AnaptysBio on 13 of the 17 factors compared between the two stocks.